-
Ferring announces abstract of the first prospective, multi-national, real-world study of Rekovelle® (follitropin delta) at the congress of the Pacific Society for Reproductive Medicine
in PRESS RELEASE 2023 onFerring announces abstract of the first prospective, multi-national, real-world study of Rekovelle®…
-
Approval of new medicines in 2022 sets Ferring on course for future growth and diversification
in PRESS RELEASE 2023 onApproval of new medicines in 2022 sets Ferring on course for future…
-
Ferring Pharmaceuticals appoints Pierre-Yves Berclaz as Executive Vice President, Chief Medical Officer
in PRESS RELEASE 2023 onFerring Pharmaceuticals appoints Pierre-Yves Berclaz as Executive Vice President, Chief Medical Officer…
-
Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
in PRESS RELEASE 2022 onFerring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle…
-
Ferring receives U.S. FDA approval for REBYOTA™ (fecal microbiota, live-jslm) – A novel first-in-class microbiota-based live biotherapeutic
in PRESS RELEASE 2022 onFerring receives U.S. FDA approval for REBYOTA™ (fecal microbiota, live-jslm) – A…
-
Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD)
in PRESS RELEASE 2022 on…
-
Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in Drugs
in PRESS RELEASE 2022 onPivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in…
-
Ferring Pharmaceuticals and Blackstone Life Sciences restructure novel gene therapy collaboration
in PRESS RELEASE 2022 onFerring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) voted…
-
Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660
in PRESS RELEASE 2022 onFerring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) voted…
-
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based Live Biotherapeutic
in PRESS RELEASE 2022 onFerring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) will hold a meeting on September 22, 2022…
Author archive for celia
Articles by: celia
